Green Cross eying sales of 50 billion won with new drug

Published: 2011-08-17 06:56:00

Updated: 2011-08-17 06:56:00

Green Cross Corp. said Friday it has signed a co-promotion agreement with LG Life Sciences to market “Shinbaro,” a new drug for osteoarthritis in a bid to raise 50 billion won in domestic sales within the next five years.

Shinbaro is Korea’s fourth homegrown osteoarthritis medicine containing ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK